Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Notes Payables (2021 - 2025)

Coeptis Therapeutics Holdings has reported Notes Payables over the past 5 years, most recently at $100000.0 for Q4 2025.

  • Quarterly results put Notes Payables at $100000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $100000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $100000.0, changed 0.0%.
  • Notes Payables for Q4 2025 was $100000.0 at Coeptis Therapeutics Holdings, roughly flat from $100000.0 in the prior quarter.
  • Over the last five years, Notes Payables for COEPW hit a ceiling of $2.4 million in Q4 2021 and a floor of $100000.0 in Q4 2024.
  • Median Notes Payables over the past 5 years was $1.2 million (2023), compared with a mean of $1.1 million.
  • Biggest five-year swings in Notes Payables: surged 1366.67% in 2023 and later plummeted 95.43% in 2025.
  • Coeptis Therapeutics Holdings' Notes Payables stood at $2.4 million in 2021, then decreased by 23.46% to $1.8 million in 2022, then tumbled by 52.7% to $875000.0 in 2023, then plummeted by 88.57% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • The last three reported values for Notes Payables were $100000.0 (Q4 2025), $100000.0 (Q2 2025), and $100000.0 (Q1 2025) per Business Quant data.